Interestingly, the 24-month PFS rate was higher for patients with KRAS mutated tumours compared to BRAFwt/KRASwt tumours, reaching 87.5% (95% CI, 38.7 to 98.1) and 68.4% (95% CI, 35.9 to 86.8), respectively. Here, KRAS is linked to neoplasm.